Revolutions Medical appoints Cirrus Financial Communications for NASDAQ listing

Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today announced that it has engaged Cirrus Financial Communications, LLC ("Cirrus") to provide comprehensive financial marketing and investor relations services.

The goals of the proprietary Cirrus Stock Launch Program are tightly defined: maximize financial brand awareness, create a deep and highly relevant investor audience, achieve a fully liquid stock and assist the Company in attaining a listing upgrade to NASDAQ -- and accomplish these goals in the shortest time possible. Cirrus will strategically customize its program to best meet Revolutions Medical's unique needs and help the Company achieve its potential in the medical devices and imaging space.

"At a moment when health care both here and abroad has become the hottest of topics, our mission to make health care safer and less expensive could not be more timely," stated Revolutions Medical CEO Ron Wheet. "We sought out an investor relations firm with the same clear conviction of purpose, and we found it in Cirrus. Their enthusiasm, energy and dedication to our cause have been evident from the start, and their ability to best distil and communicate an investment message has already delivered early returns. We believe that with Cirrus we are best positioned to rapidly grow investor awareness and form the sort of strategic relationships necessary to fully commercialize our complementary product lines."

"We are both pleased and proud to represent Revolutions Medical, a firm at the cusp of not one but three catalyst events," stated Justin Davis, Cirrus Managing Partner. "After years of exhaustive R&D, Revolutions Medical intends to launch its three core product lines, including its flagship Rev Vac retractable safety syringe, in staged fashion in the coming months. We believe that this is the very definition of a commercial tipping point. Moreover, the capital markets path has already been blazed for the Company -- its two closest public comps already command market caps of $50 - $100 million. And from both a product cost and technical performance perspective, Revolutions Medical holds a distinct competitive advantage over both. We at Cirrus believe that this is a story now come of age, and one perfectly positioned for a high growth future."